1. Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth.
- Author
-
Oshima T, Niwa Y, Kuwata K, Srivastava A, Hyoda T, Tsuchiya Y, Kumagai M, Tsuyuguchi M, Tamaru T, Sugiyama A, Ono N, Zolboot N, Aikawa Y, Oishi S, Nonami A, Arai F, Hagihara S, Yamaguchi J, Tama F, Kunisaki Y, Yagita K, Ikeda M, Kinoshita T, Kay SA, Itami K, and Hirota T
- Subjects
- Animals, CLOCK Proteins metabolism, Carcinoma, Renal Cell pathology, Casein Kinase II antagonists & inhibitors, Cell Line, Tumor, Crystallography, X-Ray, HEK293 Cells, Humans, Kidney Neoplasms pathology, Mice, Mice, Inbred C57BL, Mice, Transgenic, Phosphorylation drug effects, Carcinoma, Renal Cell metabolism, Cell Proliferation drug effects, Circadian Clocks drug effects, Circadian Rhythm drug effects, Drug Screening Assays, Antitumor methods, Kidney Neoplasms metabolism
- Abstract
Compounds targeting the circadian clock have been identified as potential treatments for clock-related diseases, including cancer. Our cell-based phenotypic screen revealed uncharacterized clock-modulating compounds. Through affinity-based target deconvolution, we identified GO289, which strongly lengthened circadian period, as a potent and selective inhibitor of CK2. Phosphoproteomics identified multiple phosphorylation sites inhibited by GO289 on clock proteins, including PER2 S693. Furthermore, GO289 exhibited cell type-dependent inhibition of cancer cell growth that correlated with cellular clock function. The x-ray crystal structure of the CK2α-GO289 complex revealed critical interactions between GO289 and CK2-specific residues and no direct interaction of GO289 with the hinge region that is highly conserved among kinases. The discovery of GO289 provides a direct link between the circadian clock and cancer regulation and reveals unique design principles underlying kinase selectivity.
- Published
- 2019
- Full Text
- View/download PDF